Abstract
This case report presents the therapeutic impact of radio electric asymmetric conveyor (REAC) neuroregenerative medicine treatment (REAC RGN-N) in a 10-year-old girl diagnosed with Canavan syndrome, a rare genetic disorder marked by progressive white matter degeneration in the brain. This condition, caused by aspartoacylase deficiency, leads to an accumulation of N-acetyl-L-aspartic acid (NAA), resulting in severe motor impairment, muscle tone abnormalities, and developmental delays. The patient received REAC RGN-N treatment, administered via the REAC - BENE mod 110 (ASMED®, Scandicci, Italy), specifically configured for RGN-N therapy. The protocol consisted of four 6-hour sessions completed over a 24-hour cycle. Following this initial treatment, the patient showed notable improvements in head and trunk control, muscle tone, and swallowing function. Head and trunk control increased from 20 to 30 on the trunk control measurement scale (TCMS), spasticity decreased from a score of 3 to 1 on the Ashworth scale, and her swallowing ability progressed from level 5 to level 7 on the functional oral intake scale (FOIS), allowing her to handle a wider range of food textures independently. These improvements were assessed six months after the end of the first treatment cycle, suggesting a degree of stability in the therapeutic effects observed. Although further studies could support these findings, the rarity of Canavan syndrome presents challenges for conducting additional targeted research. REAC RGN-N treatment is typically repeated in cycles every 4-6 months, depending on clinical severity, to sustain therapeutic benefits. This case report offers initial evidence that REAC RGN-N may provide meaningful, stable improvements for pediatric patients with neurodegenerative conditions, addressing motor and sensory impairments with potential long-term benefits.